# Vera Therapeutics Inc. (VERA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $35.89, market value $2.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Vera Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 6.3×**. The shares trade at 6.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -13.1%** (5-yr avg -9.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -49.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -69.5%**. Earnings per share fell 69.5%.

## Financial health
- **Debt to equity: 0.12**. Debt is 0.12 times equity: a conservative balance sheet.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vera Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Vera Therapeutics Inc.; the consensus is strong_buy, with an average price target of $77.14 (+115% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 63.9%** (YTD -29.1%, 3-mo 11.1%). The shares are up 63.9% over twelve months including dividends.
- **From 52-week high: -36.0%** (58.0% above the low). Trading 36% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.07** (volatility 60%). Beta of 1.07 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VERA · Page: https://foliofundamentals.com/stocks/vera

Not investment advice.